

# Anti-PDL2 (soluble form) [Z64P2D3\*H4] mAb

**Catalogue number:** 152795

**Sub-type:** Primary antibody

**Images:**

## Contributor

**Inventor:** Ayham Alnabulsi

**Institute:** Vertebrate Antibodies Limited

**Images:**

## Tool details

**\*FOR RESEARCH USE ONLY**

**Name:** Anti-PDL2 (soluble form) [Z64P2D3\*H4] mAb

**Alternate name:** B7 dendritic cell molecule, B7-DC, B7DC, bA574F11.2, Btdc, Butyrophilin B7 DC, Butyrophilin B7-DC, Butyrophilin B7DC, CD 273, CD273, CD273 antigen, MGC142238, MGC14224, PD 1 ligand 2, PD L2, PD-1 ligand 2, PD-L2, PD1 ligand 2, PD1L2\_HUMAN, PDCD 1 ligand 2, PDCD1 ligand 2

**Class:** Monoclonal

**Conjugate:** Unconjugated

**Description:** Monoclonal antibody which can aid understanding of programmed death ligand 2, in the secreted form. Background and Research Application PDL2 is involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.). PDL2 is an immune checkpoint receptor ligand which plays a role in negative regulation of the adaptive immune response. PD-L2 is one of two known ligands for Programmed cell death protein 1 (PD-1). PD-1, is a key immune checkpoint. Currently several anti-PD-1 antibodies or blockers are in cancer clinical trials and showing promising outcomes. This antibody will allow scientists examine, for the first time, the clinical significance of PDL2-secreted form.

**Purpose:**

**Parental cell:**

**Organism:**

**Tissue:**

**Model:**

**Gender:**

**Isotype:** IgG2b kappa

**Reactivity:** Human

**Selectivity:**

**Host:**

Mouse

**Immunogen:** Ovalbumin-conjugated synthetic peptide KAVFFKRHN

**Immunogen UNIPROT ID:** Q9BQ51

**Sequence:**

**Growth properties:**

**Production details:**

**Formulation:**

**Recommended controls:** IHC: formalin-fixed, paraffin-embedded multi tumour tissue microarray

**Bacterial resistance:**

**Selectable markers:**

**Additional notes:**

## Target details

**Target:** Programmed Cell Death 1 Ligand 2 (PDL2-Soluble form)

**Target alternate names:**

**Target background:** Monoclonal antibody which can aid understanding of programmed death ligand 2, in the secreted form. Background and Research Application PDL2 is involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.). PDL2 is an immune checkpoint receptor ligand which plays a role in negative regulation of the adaptive immune response. PD-L2 is one of two known ligands for Programmed cell death protein 1 (PD-1). PD-1, is a key immune checkpoint. Currently several anti-PD-1 antibodies or blockers are in cancer clinical trials and showing promising outcomes. This antibody will allow scientists examine, for the first time, the clinical significance of PDL2-secreted form.

**Molecular weight:**

**Ic50:**

## Applications

**Application:** ELISA ; IHC ; WB

**Application notes:**

## Handling

**Format:** Liquid

**Concentration:** 1 mg/ml

**Passage number:**

**Growth medium:**

**Temperature:**

**Atmosphere:**

**Volume:**

**Storage medium:**

**Storage buffer:** PBS with 0.02% azide

**Storage conditions:** Store at -20° C frozen. Avoid repeated freeze / thaw cycles

**Shipping conditions:** Shipping at 4° C

## Related tools

**Related tools:** Anti-PDL2 (soluble form), Recombinant [Z64P2D3\*H4]

## References

**References:** Gilley J et al. Neurobiol Aging. 2016 Mar;39:1-18; PMID: 26923397

CancerTools.org